Form 4: Amneal Pharmaceuticals Executive Vice President Nikita Shah Reports Stock Transactions
SEC Form 4
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reports multiple transactions involving Class A Common Stock and Restricted Stock Units.
Summary
- Nikita Shah, an Executive Vice President at Amneal Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- The reported transactions include the vesting of restricted stock units and performance-based restricted stock units, as well as the withholding of shares to cover tax obligations.
- On March 3, 2025, transactions involved the vesting of 36,232 and 45,872 restricted stock units, and 144,928 performance-based restricted stock units.
- Shares were also withheld to satisfy tax obligations, with prices at $8.76.
- On March 4, 2025, additional restricted stock units vested, and shares were withheld for taxes at a price of $8.84.
- Following these transactions, Shah directly owns 438,069 shares of Class A Common Stock.
- The filing also details the vesting schedules and conditions for various restricted stock unit grants.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The document details vesting schedules for various restricted stock unit grants, including performance-based units that vest based on the company's stock price performance over a three-year period ending February 28, 2028.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
- The vesting schedules and performance-based conditions of the restricted stock units are typical compensation mechanisms used to align management's interests with those of shareholders.
- Comparable companies in the pharmaceutical industry, such as Teva Pharmaceutical Industries and Mylan (now Viatris), also utilize stock-based compensation and are subject to similar reporting requirements.
Stakeholder Impact
- The transactions reported may influence investor perception of the company's stock.
- The vesting of stock units impacts the executive's personal holdings and alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Reporting person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. |
| 03/03/2022 | The reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2023 | The reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/04/2024 | The Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2025 | Multiple transactions involving Class A Common Stock and Restricted Stock Units occurred. |
| 03/04/2025 | Additional transactions involving Class A Common Stock and Restricted Stock Units occurred. |
| 02/28/2028 | Last day of the performance period for performance-based restricted stock units granted on March 3, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.